Search results for "ezetimibe"

showing 5 items of 65 documents

An Update on the Role of the Quality of LDL in Cardiovascular Risk:The Contribution of the Universities of Palermo and Zurich

2007

Low density lipoproteins (LDL) size seems to be an important predictor of cardiovascular events and progression of coronary artery disease and the predominance of small dense LDL have been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. We recently showed increased LDL size or higher levels of small, dense LDL in different categories of patients at higher cardiovascular risk, such as those with coronary (including acute myocardial infarction) and non-coronary (including carotid disease, abdominal aortic aneurysm and peripheral arterial disease) forms of atherosclerosis or metabolic diseases (including type-II diabet…

medicine.medical_specialtyStatinUniversitiesmedicine.drug_classCoronary artery diseaseEzetimibeInternal medicineDrug DiscoverymedicineHumansPharmacology (medical)RosuvastatinCholesterol absorption inhibitorParticle SizeRisk factorNational Cholesterol Education Programbusiness.industrymedicine.diseasePolycystic ovaryLipoproteins LDLItalyCardiovascular DiseasesCardiologylipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessSwitzerlandmedicine.drugRecent Patents on Cardiovascular Drug Discovery
researchProduct

Who needs to care about small, dense low-density lipoproteins?

2007

Summary Background:  Increasing evidence suggest that the ‘quality’ rather than only the ‘quantity’ of low-density lipoprotein (LDL) exerts a great influence on the cardiovascular risk. Small, dense LDL seem to be an important predictor of cardiovascular events and progression of coronary artery disease (CAD) and their predominance has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. Discussion:  Some studies showed in past years that small, dense LDL are usually elevated in patients at very high cardiovascular risk, such as those with CAD and type 2 diabetes. More recently elevated levels of these particles hav…

medicine.medical_specialtyStatinbusiness.industrymedicine.drug_classCholesterolGeneral MedicinePolycystic ovarychemistry.chemical_compoundEndocrinologychemistryEzetimibeInternal medicineMedicinelipids (amino acids peptides and proteins)Cholesterol absorption inhibitorRosuvastatinbusinessNational Cholesterol Education Programmedicine.drugLipoproteinInternational Journal of Clinical Practice
researchProduct

2214Prevalence and severity of coronary disease in patients with familial hypercholesterolemia hospitalized for an acute myocardial infarction: data …

2019

Abstract Aim Individuals with heterozygous familial hypercholesterolemia (FH) are at high risk of early myocardial infarction (MI). However, coronary artery disease (CAD) burden of FH remains not well described. From a large database of a regional registry of acute MI, we aimed to address prevalence of FH and severity of CAD. Methods Consecutive patients hospitalized with MI in a multicentre database from 2001–2017 were considered. An algorithm, adapted from Dutch Lipid Clinic Network criteria, was built upon 4 variables (LDL-cholesterol (LDL-C) and lipid lowering agents, premature and family history of CAD) to identify FH probabilities. Results Among the 11624 patients included in the surv…

medicine.medical_specialtybusiness.industryCoronary arteriosclerosisFamilial hypercholesterolemiaCoronary diseasemedicine.diseaseEzetimibeInternal medicineDiabetes mellitusEpidemiologymedicineIn patientMyocardial infarctionCardiology and Cardiovascular Medicinebusinessmedicine.drugEuropean Heart Journal
researchProduct

Importancia de la dislipidemia en la enfermedad cardiovascular: un punto de vista

2015

The authors present their view on the prevention of cardiovascular diseases, accepting the European ESC/EAS guidelines. They consider that the aim of the lipid control, based on LDL-C goals, is essential for the prevention and treatment of cardiovascular diseases. In subjects with metabolic syndrome (mainly, abdominal obesity, pre-diabetes and diabetes), the primary objective should be apoB or Non-HDL-C, which are better associated with cardiovascular risk. The treatment must be lifestyle changes and control of other risk factors. After calculating cardiovascular risk, statins are the first therapeutic step, with the strength and dose needed to achieve LDL-C goals. If targets are not achiev…

medicine.medical_specialtybusiness.industryDiseaseArteriosclerosismedicine.diseaseEzetimibeAge groupsDiabetes mellitusInternal medicinemedicinelipids (amino acids peptides and proteins)Pharmacology (medical)Lipid controlmedicine.symptomMetabolic syndromeCardiology and Cardiovascular MedicinebusinessAbdominal obesitymedicine.drugClínica e Investigación en Arteriosclerosis
researchProduct

The Clinical Relevance of LDL Size and Subclasses Modulation in Patients with Type-2 Diabetes

2007

increasing evidence suggest that the "quality" rather than only the "quantity" of low density lipoproteins (LDL) exerts a great influence on the cardiovascular risk. Hypertriglyceridemia, low HDL-cholesterol and increased levels of small dense LDL characterise diabetic dyslipidemia. in subjects with type-2 diabetes LDL size seems also to represent a good marker of clinical apparent and non-apparent atherosclerosis. Recently, the Coordinating Committee of the National Cholesterol Education Program stated that high-risk patients may benefit of stronger therapeutical approaches, a category of subjects that include those with type-2 diabetes. Screening for the presence of small, dense LDL may p…

medicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismAtorvastatinPharmacologyEndocrinologyEzetimibeInternal medicineInternal MedicineHumansMedicineGemfibrozilCholesterol absorption inhibitorNational Cholesterol Education ProgramHypolipidemic Agentssmall dense LDL subclasses fibrates statins ezetimibe diabetes high-riskFenofibrateBezafibratebusiness.industryHypertriglyceridemiaGeneral Medicinemedicine.diseaseLipoproteins LDLMolecular WeightEndocrinologyDiabetes Mellitus Type 2lipids (amino acids peptides and proteins)businessmedicine.drugExperimental and Clinical Endocrinology & Diabetes
researchProduct